These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38756241)

  • 1. Commercial coverage of specialty drugs, 2017-2021.
    Rucker JA; Beinfeld MT; Jenkins NB; Enright DE; Henderson RR; Chambers JD
    Health Aff Sch; 2023 Aug; 1(2):qxad030. PubMed ID: 38756241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration-expedited programs.
    Jenkins NB; Rucker JA; Klimchak AC; Sedita LE; Chambers JD
    J Manag Care Spec Pharm; 2023 May; 29(5):472-479. PubMed ID: 36864544
    [No Abstract]   [Full Text] [Related]  

  • 3. US commercial health plan coverage dynamics in pulmonary arterial hypertension therapies.
    Rucker JA; Beinfeld MT; Enright DE; Germack HD; Panjabi S; Chakinala MM; Chambers JD
    J Manag Care Spec Pharm; 2024 Jun; 30(6):541-548. PubMed ID: 38824632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
    Panzer AD; Ingham M; Martin S; Chambers JD
    J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
    [No Abstract]   [Full Text] [Related]  

  • 5. Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.
    Chambers JD; Enright DE; Panzer AD; Cohen JT; Ollendorf DA; Neumann PJ
    J Manag Care Spec Pharm; 2023 Mar; 29(3):257-264. PubMed ID: 36840954
    [No Abstract]   [Full Text] [Related]  

  • 6. Specialty drug coverage varies between health plans' medical and pharmacy benefit policies.
    Levine AA; Panzer AD; Kauf TL; O'Sullivan AK; Strand L; Chambers JD
    J Manag Care Spec Pharm; 2023 Jun; 29(6):607-613. PubMed ID: 37276044
    [No Abstract]   [Full Text] [Related]  

  • 7. Specialty Drug Coverage Varies Across Commercial Health Plans In The US.
    Chambers JD; Kim DD; Pope EF; Graff JS; Wilkinson CL; Neumann PJ
    Health Aff (Millwood); 2018 Jul; 37(7):1041-1047. PubMed ID: 29985695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in access to hemophilia A treatments in the United States.
    Margaretos NM; Patel AM; Panzer AD; Lai RC; Whiteley J; Chambers JD
    J Med Econ; 2021; 24(1):1143-1148. PubMed ID: 34538215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variation in health plan coverage of ESAs for anemia due to chronic kidney disease.
    Margaretos NM; Panzer AD; Lai RC; Sanon M; Michalopoulos E; Redmond AM; Moghadam R; Chambers JD
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1221-1229. PubMed ID: 34464213
    [No Abstract]   [Full Text] [Related]  

  • 10. Characterizing health plan evidence review practices.
    Panzer AD; Enright DE; Graff J; Chambers JD
    J Manag Care Spec Pharm; 2022 Sep; 28(9):1053-1058. PubMed ID: 36001106
    [No Abstract]   [Full Text] [Related]  

  • 11. Patients' access to rare neuromuscular disease therapies varies across US private insurers.
    Margaretos NM; Bawa K; Engmann NJ; Chambers JD
    Orphanet J Rare Dis; 2022 Feb; 17(1):36. PubMed ID: 35123543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs.
    Chambers JD; Wilkinson CL; Anderson JE; Chenoweth MD
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1176-81. PubMed ID: 27668566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balancing Evidence and Need: Variation in US Commercial Payer Coverage of Esketamine.
    Ochigbo EB; Beinfeld MT; Chambers JD
    Clin Ther; 2024 Oct; 46(10):808-811. PubMed ID: 39039006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial Insurance Companies.
    Learned C; Alsukait S; Fiumara KR; Ortega M; Chambers JD; Rosmarin D
    J Psoriasis Psoriatic Arthritis; 2022 Oct; 7(4):160-163. PubMed ID: 39296962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients' access to 2018 FDA-approved drugs 1 year post approval.
    Panzer AD; Margaretos NM; Bridger N; Osani MC; Lai RC; Chambers JD
    Am J Manag Care; 2022 Apr; 28(4):e153-e156. PubMed ID: 35420754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease.
    Lin PJ; Levine A; Rucker J; Chambers JD
    Alzheimers Dement; 2023 Aug; 19(8):3654-3669. PubMed ID: 36852834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited role of patient input in specialty drug coverage policies.
    D'Cruz B; Graff JS; Panzer AD; Chambers JD
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1067-1076. PubMed ID: 34337996
    [No Abstract]   [Full Text] [Related]  

  • 18. Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug Coverage.
    Chambers JD; Panzer AD; Pope EF; Graff JS; Neumann PJ
    Health Aff (Millwood); 2019 Nov; 38(11):1882-1886. PubMed ID: 31682500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies.
    Chambers JD; Pope EF; Wilkinson CL; Neumann PJ
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1240-1246. PubMed ID: 30479201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
    Robinson SW; Brantley K; Liow C; Teagarden JR
    J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.